NCT01116271View on ClinicalTrials.gov

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Colorectal Cancer
Interventions
DRUG

AZD6244

50 or 75mg, capsules, PO, BID, 28 days

DRUG

Irinotecan

180mg/m2, IV, Day 1\& 15 of each cycle

Trial Locations (12)

Unknown

Research Site, Los Angeles

Research Site, Palm Springs

Research Site, Aurora

Research Site, New Haven

Research Site, Newark

Research Site, Miami Beach

Research Site, New York

Reserach Site, Chapel Hill

Research Site, Greenville

Research Site, Washington

Research Site, Philadelphia

Research Site, Seattle

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01116271 - Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | Biotech Hunter | Biotech Hunter